June 14, 2024


Extraordinary care

SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients

LMF Acquisition Opportunities Inc.

LMF Acquisition Possibilities Inc.

Designation will help allow accelerated regulatory evaluate of impending pivotal scientific trial for remedy in adult patients with acute kidney personal injury

DENVER, CO and TAMPA, FL, May 03, 2022 (World NEWSWIRE) — SeaStar Professional medical, a clinical technological know-how company building proprietary methods to reduce the repercussions of hyperinflammation on important organs, and LMF Acquisition Alternatives, Inc. (Nasdaq: LMAO) (“LMAO”), a particular reason acquisition enterprise, these days introduced that SeaStar Medical’s Selective Cytopheretic Gadget (SCD) has received a Breakthrough System Designation from the U.S. Food stuff and Drug Administration (Fda).

The SCD is a patented, mobile-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to deal with hyperinflammation. Neutrophils and monocytes are the mobile mediators that travel systemic irritation, which when spreading uncontrollably as a result of the entire body can guide to organ hurt, organ failure or loss of life. The SCD technologies targets the cellular motorists of inflammation to restore immune stability in the system and probably reverse the harm.

The Breakthrough Gadget Designation acknowledges our platform’s probable to deal with one particular of the greatest unmet clinical demands in handling acute kidney harm,” stated Eric Schlorff, President and Chief Govt Officer of SeaStar Clinical. “The medical facts created to date in both of those grown ups and pediatrics, has revealed a reduction of mortality and dialysis dependency in this critically-unwell individual population. We appear forward to functioning with the Food and drug administration to supply a novel therapy that addresses activated neutrophils and monocytes.”

The Breakthrough Device Designation is predicted to allow expedited regulatory assessment to progress SeaStar Medical’s impending pivotal scientific demo for therapy of acute kidney injury (AKI) in grown ups.

In accordance to The Financial Implications of Acute Kidney Damage by Nephron in 2017, AKI is associated with an enhance in hospitalization costs that are believed between $5.4 and $24. billion on a yearly basis in the United States. As a result, SeaStar Health care estimates a multi billion dollar initial goal industry in the US for the SCD, with prospective for expansion into acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO) and other indications.

“This breakthrough designation should really assistance accelerate the FDA’s timeline all-around taking into consideration the SCD’s impending IDE approval for use with acute kidney injury patients,” reported Eric Schlorff. “Hyperinflammation can be a devastating component in lots of diseases which include acute kidney damage, Covid-19 and acute respiratory distress syndrome. If accredited, the SCD would supply clinicians a potent weapon to enable lower the consequences of hyperinflammation and likely save life.”

As beforehand introduced, SeaStar Clinical and LMAO entered into a definitive settlement for a business blend transaction whereby SeaStar Professional medical will come to be publicly outlined on Nasdaq, subject matter to approval by stockholders of LMAO and other customary closing circumstances.

About SeaStar Health care, Inc.

Denver-dependent SeaStar Health care is a privately held health-related technology business that is focusing on redefining how extracorporeal therapies may perhaps lower the repercussions of extreme inflammation on crucial organs. SeaStar Medical’s novel systems depend on science and innovation to supply lifetime-saving solutions to critically sick sufferers. It is producing and commercializing extracorporeal therapies that target the effector cells that generate systemic swelling, leading to immediate tissue harm and secreting a range of professional-inflammatory cytokines that initiate and propagate imbalanced immune responses. For much more information take a look at http://www.seastarmedical.com/ or visit us on LinkedIn or Twitter.

About LMF Acquisition Alternatives, Inc.

LMF Acquisition Options, Inc. (Nasdaq: LMAO) is a distinctive purpose acquisition company shaped for the function of effecting a merger, funds inventory exchange, asset acquisition, stock buy, reorganization or equivalent business mix with just one or a lot more corporations. LMAO is led by Bruce M. Rodgers, Main Executive Officer and Chairman of the Board. For additional information and facts, take a look at www.lmfacquisitions.com.

Ahead-Looking Statements

This press launch has specific ahead-wanting statements in the that means of the “safe harbor” provisions of the Non-public Securities Litigation Reform Act of 1955. These ahead-on the lookout statements involve, with no limitation, LMAO’s and SeaStar Medical’s expectations with regard to the proposed business mixture between LMAO and SeaStar Clinical, such as statements about the benefits of the transaction, the expected timing of the transaction, the implied valuation of SeaStar Healthcare, the solutions made available by SeaStar Professional medical and the markets in which it operates, and SeaStar Medical’s projected upcoming results. Words and phrases this kind of as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will proceed,” “will possible outcome,” and similar expressions are supposed to indentify these kinds of ahead-wanting statements. Forward-seeking statements are predictions, projections and other statements about long term events that are based mostly on latest anticipations and assumptions and, as a result, are issue to significant challenges and uncertainties that could lead to the real outcomes to vary materially from the predicted results. Most of these aspects are exterior LMAO’s and SeaStar Medical’s command and are hard to forecast. Factors that may well result in actual future gatherings to vary materially from the expected results, include things like, but are not restricted to: (i) the risk that the business mixture transaction in between SeaStar Health-related and LMAO could not be completed in a well timed method or at all, which may possibly adversely have an affect on the price tag of LMAO’s securities, (ii) the chance that the transaction might not be done by LMAO’s business blend deadline, even if prolonged by its sponsor, (iii) the failure to fulfill the conditions to the consummation of the transaction, together with the adoption of the agreement and prepare of merger (“Merger Agreement”) by the stockholders of LMAO and the satisfaction of the bare minimum have confidence in account volume subsequent redemptions by LMAO’s general public stockholders, (iv) the incidence of any function, transform or other circumstance that could give increase to the termination of the Merger Settlement, (v) the receipt of an unsolicited give from yet another celebration for an choice transaction that could interfere with the business combination, (vi) the influence of the announcement or pendency of the transaction on SeaStar Medical’s business interactions, efficiency, and business usually, (vii) the lack of ability to understand the predicted positive aspects of the business mix, which may be afflicted by, between other things, competition and the ability of the submit-mix firm to improve and manage progress profitability and retain its important staff, (viii) expenditures similar to the business mixture, (ix) the result of any authorized proceedings that might be instituted against SeaStar Health care or LMAO pursuing the announcement of the proposed business blend, (x) the means to preserve the listing of LMAO’s securities on the Nasdaq, (xi) the capability to put into practice business strategies, forecasts, and other anticipations following the completion of the proposed business combination, and determine and recognize further alternatives, (xii) the threat of downturns and the probability of swift alter in the really competitive marketplace in which SeaStar Clinical operates, (xiii) the danger that SeaStar Professional medical and its existing and long term collaborators are not able to productively create and commercialize SeaStar Medical’s goods or products and services, or knowledge sizeable delays in accomplishing so, including failure to attain acceptance of its items by relevant federal and point out regulators, (xiv) the risk that SeaStar Professional medical may well hardly ever obtain or sustain profitability (xv) the possibility that SeaStar Professional medical might have to have to elevate more funds to execute its business plan, which numerous not be readily available on satisfactory conditions or at all (xvi) the risk that 3rd-events suppliers and suppliers are not ready to completely and well timed meet up with their obligations, (xvii) the chance of product or service legal responsibility or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and solutions, (xviii) the chance that SeaStar Health-related is unable to secure or defend its mental property, (xix) the possibility that the post-mixture company’s securities will not be accepted for listing on Nasdaq or if authorized, sustain the listing and (xx) other pitfalls and uncertainties indicated from time to time in the proxy statement / prospectus to be filed relating to the business blend, like people less than the “Risk Factors” area therein and in LMAO’s other filings with the SEC. The foregoing list of factors is not exhaustive. Ahead-on the lookout statements talk only as of the date they are designed. Audience are cautioned not to put undue reliance on ahead-on the lookout statements, and SeaStar Healthcare and LMAO assume no obligation and do not intend to update or revise these ahead-wanting statements, no matter whether as a outcome of new facts, future events, or normally.

Critical Information and Where to Discover It

In relationship with the business mix transaction, LMAO intends to file a registration statement on Variety S-4 (the “Registration Statement”) with the SEC, which will involve a preliminary proxy statement to be dispersed to holders of LMAO’s frequent inventory in connection with LMAO’s solicitation of proxies for the vote by LMAO’s stockholders with respect to the transaction and other issues as described in the Registration Assertion, as nicely as the prospectus relating to the give of the securities to be issued to SeaStar Medical’s stockholders in link with the transaction. Just after the Registration Statement has been submitted and declared productive, LMAO will mail a definitive proxy assertion, when accessible, to its stockholders. Investors and safety holders and other interested get-togethers are urged to examine the proxy statement/prospectus, any amendments thereto and any other documents filed with the SEC very carefully and in their entirety when they grow to be obtainable for the reason that they will incorporate vital facts about LMAO, SeaStar Healthcare and the transaction. Traders and safety holders may perhaps acquire free copies of the preliminary proxy assertion/prospectus and definitive proxy assertion/prospectus (when offered) and other paperwork filed with the U.S. Securities and Exchange Fee (the “SEC”) by LMAO by the site preserved by the SEC at http://www.sec.gov, or by directing a ask for to: LMF Acquisition Possibilities, Inc., 1200 Platt Road, Suite 1000 Tampa, FL 33602.

Individuals in Solicitation

LMAO and SeaStar Medical and their respective directors and sure of their respective executive officers and other members of management and employees might be regarded participants in the solicitation of proxies with respect to the business mixture transaction. Info about the directors and govt officers of LMAO is set forth in its Yearly Report on Sort 10-K for the fiscal 12 months ended December 31, 2021. Extra data regarding the participants in the proxy solicitation and a description of their direct and oblique passions, by safety holdings or usually, will be bundled in the proxy statement/prospectus and other relevant resources to be filed with the SEC relating to the business mixture transaction when they grow to be accessible. Stockholders, potential investors and other intrigued individuals must read the proxy statement/prospectus carefully when it gets readily available in advance of earning any voting or financial investment conclusions. When obtainable, these paperwork can be acquired free of cost from the resources indicated over.

No Offer you or Solicitation

This press release shall not constitute an provide to promote or the solicitation of an offer to purchase any securities, nor shall there be any sale of securities in any jurisdiction in which these types of give, solicitation or sale would be illegal prior to registration or qualification beneath the securities rules of any this sort of jurisdiction. No supplying of securities shall be produced except by indicates of a prospectus conference the requirements of Part 10 of the U.S. Securities Act of 1933, as amended.

Media Relations Make contact with:
Patty Caballero
E mail: [email protected]
Tel: 862.216.7523

Investor Relations Speak to:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
E mail: lmao@crescendo-ir.com
Tel: 212-671-1020